journal article·2024-12-24Open access

Nano Delivery System for Atherosclerosis

Zhuoyi Rong, Xuan He, Tianjian Fan, Haitao Zhang

Abstract

Atherosclerosis, a pathological process propelled by inflammatory mediators and lipids, is a principal contributor to cardiovascular disease incidents. Currently, drug therapy, the primary therapeutic strategy for atherosclerosis, faces challenges such as poor stability and significant side effects. The advent of nanomaterials has garnered considerable attention from scientific researchers. Nanoparticles, such as liposomes and polymeric nanoparticles, have been developed for drug delivery in atherosclerosis treatment. This review will focus on how nanoparticles effectively improve drug safety and efficacy, as well as the continuous development and optimization of nanoparticles of the same material and further explore current challenges and future opportunities in this field.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Atherosclerosis and Cardiovascular Diseases

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang 421001, China

Funding

Natural Science Foundation of Hunan Province · Research Foundation of Education Bureau of Hunan Province · Scientific Research Project of Hunan Provincial Health Commission · Innovation and Entrepreneurship Training Program for College Students in Hunan Province

References (100+)

Show source-provided references
1. (2022, December 06). Cardiovascular Diseases (CVDs) [EB/OL]. Available online: https://www.who.int/zh/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds).
2. (2022, December 06). Non communicable Diseases [EB/OL]. Available online: https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases.
3. Therapeutic strategies for atherosclerosis and atherothrombosis: Past, present and future10.1160/TH16-10-0814 ↗
4. Zhu, Y., Xian, X., Wang, Z., Bi, Y., Chen, Q., Han, X., Tang, D., and Chen, R. (2018). Research Progress on the Relationship between Atherosclerosis and Inflammation. Biomolecules, 8.10.3390/biom8030080 ↗
5. Immunity and Inflammation in Atherosclerosis10.1161/CIRCRESAHA.118.313591 ↗
7. Recent advances in nanomaterials for therapy and diagnosis for atherosclerosis10.1016/j.addr.2021.01.005 ↗
8. Proteomic Characterization of Atherosclerotic Lesions In Situ Using Percutaneous Coronary Intervention Angioplasty Balloons—Brief Report10.1161/ATVBAHA.122.317491 ↗
9. Coronary artery bypass grafting: Part 2–optimizing outcomes and future prospects10.1093/eurheartj/eht284 ↗
10. Cholesterol Biosynthesis: A Mechanistic Overview10.1021/acs.biochem.6b00342 ↗
11. Nucleic Acid–Based Therapies for Atherosclerosis10.1007/s11883-020-0826-2 ↗
12. Impact of miRNA in Atherosclerosis10.1161/ATVBAHA.118.310227 ↗
13. Synthesis of siRNA nanoparticles to silence plaque-destabilizing gene in atherosclerotic lesional macrophages10.1038/s41596-021-00665-4 ↗
14. Macrophage-Targeted Gene Therapy to Improve the Atherosclerotic Plaque Stability10.1016/j.matt.2020.08.009 ↗
15. Nanomedicine Meets microRNA: Current Advances in RNA-Based Nanotherapies for Atherosclerosis10.1161/ATVBAHA.116.307481 ↗
16. Yuanyuan, G., Fujun, W., Sunli, W., Xinhua, L., Yu, H., Miao, X., Xiaoer, W., Wangshu, Z., Tingting, Y., and Yuehua, L. (2024). Endothelium-targeted NF-κB siRNA nanogel for magnetic resonance imaging and visualized-anti-inflammation treatment of atherosclerosis. Biomaterials, 314.10.1016/j.biomaterials.2024.122897 ↗
17. Targeted delivery of rapamycin and inhibition of platelet adhesion with multifunctional peptide nanoparticles for atherosclerosis treatment10.1016/j.jconrel.2024.10.051 ↗
18. Mengying, C., Tianxiang, Y., Hong, W., Lai, J., Qiaoling, H., and Fanzhu, L. (Asian J. Pharm. Sci., 2024). Biomimetic nanoparticles co-deliver hirudin and lumbrukinase to ameliorate thrombus and inflammation for atherosclerosis therapy, Asian J. Pharm. Sci., in press.
19. Biomimetic nanomedicines for precise atherosclerosis theranostics10.1016/j.apsb.2022.11.014 ↗
20. Inclisiran: First Approval10.1007/s40265-021-01473-6 ↗
21. Hossaini, N.S., and Huang, X. (2021). Nanotechnology for Targeted Therapy of Atherosclerosis. Front. Pharmacol, 12.10.3389/fphar.2021.755569 ↗
22. Rong, T., Wei, B., Ao, M., Zhao, H., Li, Y., Zhang, Y., Qin, Y., Zhou, J., Zhou, F., and Chen, Y. (2021). Enhanced Anti-Atherosclerotic Efficacy of pH-Responsively Releasable Ganglioside GM3 Delivered by Reconstituted High-Density Lipoprotein. Int. J. Mol. Sci., 22.10.3390/ijms222413624 ↗
23. Cyclodextrin-mediated conjugation of macrophage and liposomes for treatment of atherosclerosis10.1016/j.jconrel.2022.06.053 ↗
24. Liposomes: Advancements and innovation in the manufacturing process10.1016/j.addr.2020.07.002 ↗
25. Recent Developments of Liposomes as Nanocarriers for Theranostic Applications10.7150/thno.15464 ↗
26. Nanoparticle Therapy for Vascular Diseases10.1161/ATVBAHA.118.311569 ↗
27. Liposomal Nanotherapy for Treatment of Atherosclerosis10.1002/adhm.202000465 ↗
28. MiR-146a encapsulated liposomes reduce vascular inflammatory responses through decrease of ICAM-1 expression, macrophage activation, and foam cell formation10.1039/D2NR03280E ↗
29. Complement Receptor Targeted Liposomes Encapsulating the Liver X Receptor Agonist GW3965 Accumulate in and Stabilize Atherosclerotic Plaques10.1002/adhm.202000043 ↗
30. Multifunctional Nanoparticles Facilitate Molecular Targeting and miRNA Delivery to Inhibit Atherosclerosis in ApoE–/– Mice10.1021/acsnano.5b02611 ↗
31. Neutrophil extracellular traps: A catalyst for atherosclerosis10.1007/s11010-024-04931-3 ↗
32. Monti, M., De Rosa, V., Iommelli, F., Carriero, M.V., Terlizzi, C., Camerlingo, R., Belli, S., Fonti, R., Di Minno, G., and Del Vecchio, S. (2018). Neutrophil Extracellular Traps as an Adhesion Substrate for Different Tumor Cells Expressing RGD-Binding Integrins. Int. J. Mol. Sci., 19.10.3390/ijms19082350 ↗
33. Integrin signaling in atherosclerosis
34. Monti, M., Iommelli, F., De Rosa, V., Carriero, M.V., Miceli, R., Camerlingo, R., Di Minno, G., and Del Vecchio, S. (2017). Integrin-dependent cell adhesion to neutrophil extracellular traps through engagement of fibronectin in neutrophil-like cells. PLoS ONE, 12.10.1371/journal.pone.0171362 ↗
35. An elastase-inhibiting, plaque-targeting and neutrophil-hitchhiking liposome against atherosclerosis10.1016/j.actbio.2023.11.020 ↗
36. Co-Targeting E-Selectin/CXCR4 with GMI-1359 Facilitates AML Stem Cell Mobilization and Protects BM Niches from Anti-Leukemia Therapy10.1182/blood-2021-153661 ↗
37. Specific E-selectin targeting with a superparamagnetic MRI contrast agent10.1002/cmmi.87 ↗
38. Synergistic effects of liposomes encapsulating atorvastatin calcium and curcumin and targeting dysfunctional endothelial cells in reducing atherosclerosis10.2147/IJN.S189819 ↗
39. Hybrid nanoparticles improve targeting to inflammatory macrophages through phagocytic signals10.1016/j.jconrel.2015.09.027 ↗
40. Macrophage-targeted, enzyme-triggered fluorescence switch-on system for detection of embolism-vulnerable atherosclerotic plaques10.1016/j.jconrel.2019.03.025 ↗
41. An apoptotic body-biomimic liposome in situ upregulates anti-inflammatory macrophages for stabilization of atherosclerotic plaques10.1016/j.jconrel.2019.10.043 ↗
42. Site-specific targeting of nanoparticle prednisolone reduces in-stent restenosis in a rabbit model of established atheroma10.1161/ATVBAHA.108.170662 ↗
43. Nanoliposomes as the adjuvant delivery systems in cancer immunotherapy10.1002/jcp.26361 ↗
44. PCSK9 and atherosclerosis: Looking beyond LDL regulation10.1111/eci.13459 ↗
45. Chen, J., Xiang, X., Nie, L., Guo, X., Zhang, F., Wen, C., Xia, Y., and Mao, L. (2023). The emerging role of Th1 cells in atherosclerosis and its implications for therapy. Front. Immunol., 13.10.3389/fimmu.2022.1079668 ↗
46. Inflammation in atherosclerosis10.1016/j.acvd.2016.04.002 ↗
47. Ait-Oufella, H., Lavillegrand, J., and Tedgui, A. (2021). Regulatory T Cell-Enhancing Therapies to Treat Atherosclerosis. Cells, 10.10.3390/cells10040723 ↗
48. Baardman, J., and Lutgens, E. (2020). Regulatory T Cell Metabolism in Atherosclerosis. Metabolites, 10.10.3390/metabo10070279 ↗
49. Atherosclerosis
50. Fortified Tregs to fight atherosclerosis10.1093/cvr/cvab103 ↗
51. High density lipoprotein mimicking nanoparticles for atherosclerosis10.1186/s40580-019-0214-1 ↗
52. Pharmacokinetics and atherosclerotic lesions targeting effects of tanshinone IIA discoidal and spherical biomimetic high density lipoproteins10.1016/j.biomaterials.2012.09.058 ↗
53. Synthetic High-Density Lipoprotein-Mediated Targeted Delivery of Liver X Receptors Agonist Promotes Atherosclerosis Regression10.1016/j.ebiom.2017.12.021 ↗
54. Synthetic lipoprotein as nano-material vehicle in the targeted drug delivery10.1080/10717544.2017.1384518 ↗
55. Enhanced Cancer-Targeted Delivery Using Engineered High-Density Lipoprotein-Based Nanocarriers10.1166/jbn.2007.053 ↗
56. Targeted therapy of atherosclerosis by pH-sensitive hyaluronic acid nanoparticles co-delivering all-trans retinal and rapamycin10.1039/D1NR06514A ↗
57. Hyaluronic acid nanoparticles for active targeting atherosclerosis10.1016/j.biomaterials.2015.02.089 ↗
58. Shear stress and ROS-responsive biomimetic micelles for atherosclerosis via ROS consumption10.1016/j.msec.2021.112164 ↗
59. Reactive oxygen species (ROS)-responsive size-reducible nanoassemblies for deeper atherosclerotic plaque penetration and enhanced macrophage-targeted drug delivery
60. Nanotherapeutics for inhibition of atherogenesis and modulation of inflammation in atherosclerotic plaques10.1093/cvr/cvv237 ↗
61. Athero-inflammatory nanotherapeutics: Ferulic acid-based poly(anhydride-ester) nanoparticles attenuate foam cell formation by regulating macrophage lipogenesis and reactive oxygen species generation10.1016/j.actbio.2017.05.029 ↗
62. Oligonucleotide aggregates bind to the macrophage scavenger receptor10.1046/j.1432-1327.1999.00233.x ↗
63. Promoting the Delivery of Nanoparticles to Atherosclerotic Plaques by DNA Coating10.1021/acsami.8b17928 ↗
64. Plaque-Targeted Rapamycin Spherical Nucleic Acids for Synergistic Atherosclerosis Treatment10.1002/advs.202105875 ↗
65. Targeted polyelectrolyte complex micelles treat vascular complications in vivo [Medical Sciences]10.1073/pnas.2114842118 ↗
66. Targeting Ferroptosis: A Novel Strategy for the Treatment of Atherosclerosis10.2174/0113895575273164231130070920 ↗
67. Burtenshaw, D., Kitching, M., Redmond, E.M., Megson, I.L., and Cahill, P.A. (2019). Reactive Oxygen Species (ROS), Intimal Thickening, and Subclinical Atherosclerotic Disease. Front. Cardiovasc. Med., 6.10.3389/fcvm.2019.00089 ↗
68. Novel dual ROS-sensitive and CD44 receptor targeting nanomicelles based on oligomeric hyaluronic acid for the efficient therapy of atherosclerosis10.1016/j.carbpol.2019.115787 ↗
69. Mu, D., Li, J., Qi, Y., Sun, X., Liu, Y., Shen, S., Li, Y., Xu, B., and Zhang, B. (2020). Hyaluronic acid-coated polymeric micelles with hydrogen peroxide scavenging to encapsulate statins for alleviating atherosclerosis. J. Nanobiotechnol., 18.10.1186/s12951-020-00744-w ↗
70. ROS Responsive Nanoplatform with Two-Photon AIE Imaging for Atherosclerosis Diagnosis and “Two-Pronged” Therapy10.1002/smll.202003253 ↗
71. Biomimetic-Coated Nanoplatform with Lipid-Specific Imaging and ROS Responsiveness for Atherosclerosis-Targeted Theranostics10.1021/acsami.1c08552 ↗
72. A systematic comparison of clinically viable nanomedicines targeting HMG-CoA reductase in inflammatory atherosclerosis10.1016/j.jconrel.2017.07.013 ↗
73. Lipid nanoparticles encapsulating curcumin for imaging and stabilization of vulnerable atherosclerotic plaques via phagocytic “eat-me” signals10.1016/j.jconrel.2024.07.027 ↗
74. Preparation and characterisation of atorvastatin and curcumin-loaded chitosan nanoformulations for oral delivery in atherosclerosis10.1049/iet-nbt.2016.0062 ↗
75. Pillai, S.C., Borah, A., Le, M.N.T., Kawano, H., Hasegawa, K., and Kumar, D.S. (2021). Co-Delivery of Curcumin and Bioperine via PLGA Nanoparticles to Prevent Atherosclerotic Foam Cell Formation. Pharmaceutics, 13.10.22541/au.162126173.30070384/v1 ↗
76. Cluster of Differentiation-44-Targeting Prussian Blue Nanoparticles Onloaded with Colchicine for Atherosclerotic Plaque Regression in a Mice Model10.1021/acsbiomaterials.3c01518 ↗
77. Tang, J., Li, T., Xiong, X., Yang, Q., Su, Z., Zheng, M., and Chen, Q. (2023). Colchicine delivered by a novel nanoparticle platform alleviates atherosclerosis by targeted inhibition of NF-κB/NLRP3 pathways in inflammatory endothelial cells. J. Nanobiotechnol., 21.10.1186/s12951-023-02228-z ↗
78. Targeted Imaging in Atherosclerosis10.1021/acs.analchem.2c02644 ↗
79. Intravital lipid droplet labeling and imaging reveals the phenotypes and functions of individual macrophages in vivo10.1016/j.jlr.2022.100207 ↗
80. Progress in oral insulin delivery by PLGA nanoparticles for the management of diabetes10.1016/j.drudis.2022.103393 ↗
81. Controlled release and targeted drug delivery with poly(lactic-co-glycolic acid) nanoparticles: Reviewing two decades of research10.1007/s40005-022-00584-w ↗
82. A study of lovastatin and L-arginine co-loaded PLGA nanomedicine for enhancing nitric oxide production and eNOS expression10.1039/D1TB01455B ↗
83. Li, Y., Zhang, B., Liu, X., Wan, H., Qin, Y., Yan, H., Wang, Y., An, Y., Yang, Y., and Dai, Y. (2023). A bio-inspired nanoparticle coating for vascular healing and immunomodulatory by cGMP-PKG and NF-kappa B signaling pathways. Biomaterials, 302.10.1016/j.biomaterials.2023.122288 ↗
84. Inflammatory endothelium-targeted and cathepsin responsive nanoparticles are effective against atherosclerosis10.7150/thno.70896 ↗
85. Karami, Z., Mehrzad, J., Akrami, M., and Hosseinkhani, S. (2023). Anti-inflammation-based treatment of atherosclerosis using Gliclazide-loaded biomimetic nanoghosts. Sci. Rep., 13.10.1038/s41598-023-41136-y ↗
86. Zhu, Y., Xu, Y., Han, D., Zhang, X., Qin, C., Liu, J., Tian, L., Xu, M., Fang, Y., and Zhang, Y. (2023). Scavenger receptor-AI targeted theranostic nanoparticles for regression of atherosclerotic plaques via ABCA1 modulation. Nanomed. Nanotechnol. Biol. Med., 50.10.1016/j.nano.2023.102672 ↗
87. Cyclodextrin-loaded nanobubbles reduce cholesterol and atherosclerosis in vivo10.1093/eurheartj/ehad655.3257 ↗
88. Cyclodextrin boostered-high density lipoprotein for antiatherosclerosis by regulating cholesterol efflux and efferocytosis10.1016/j.carbpol.2022.119632 ↗
89. Poly-paclitaxel/cyclodextrin-SPION nano-assembly for magnetically guided drug delivery system10.1016/j.jconrel.2016.01.006 ↗
90. Poly-cyclodextrin and poly-paclitaxel nano-assembly for anticancer therapy10.1038/ncomms4702 ↗
91. Poly-β-cyclodextrin Supramolecular Nanoassembly with a pH-Sensitive Switch Removing Lysosomal Cholesterol Crystals for Antiatherosclerosis10.1021/acs.nanolett.1c03664 ↗
92. Macrophage Membrane-Encapsulated Dopamine-Modified Poly Cyclodextrin Multifunctional Biomimetic Nanoparticles for Atherosclerosis Therapy10.1021/acsami.4c04431 ↗
93. Polydopamine-based nanostructures: A new generation of versatile, multi-tasking, and smart theranostic tools10.1016/j.nantod.2024.102151 ↗
94. A Dual-Function CD47-Targeting Nano-Drug Delivery System Used to Regulate Immune and Anti-Inflammatory Activities in the Treatment of Atherosclerosis10.1002/adhm.202400752 ↗
95. Tu, S., Ren, W., Han, J., Cui, H., Dai, T., Lu, H., Xie, Y., He, W., and Wu, A. (2023). Polydopamine nanoparticle-mediated mild photothermal therapy for inhibiting atherosclerotic plaque progression by regulating lipid metabolism of foam cells. Regen. Biomater., 10.10.1093/rb/rbad031 ↗
96. Poly(β-amino ester)s-based nanovehicles: Structural regulation and gene delivery10.1016/j.omtn.2023.04.019 ↗
97. Poly (beta-amino ester) as an in vivo nanocarrier for therapeutic nucleic acids
98. Delivery of Anti-microRNA-712 to Inflamed Endothelial Cells Using Poly(β-amino ester) Nanoparticles Conjugated with VCAM-1 Targeting Peptide10.1002/adhm.202001894 ↗
99. Ibrutinib Inhibits BMX-Dependent Endothelial VCAM-1 Expression In Vitro and Pro-Atherosclerotic Endothelial Activation and Platelet Adhesion In Vivo10.1007/s12195-022-00723-1 ↗
100. IRF-1 and miRNA126 modulate VCAM-1 expression in response to a high-fat meal10.1161/CIRCRESAHA.112.270314 ↗